

Pier Paolo Scaglioni

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/5284792/publications.pdf](https://exaly.com/author-pdf/5284792/publications.pdf)

Version: 2025-02-01

34

PR articles

2,650

PR citations

234239

23

PR h-index

341354

33

g-index

38

documents

3704

doc citations

206347

26

h-index

5515

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2025, 15, 401-426.	25.6	9
2	Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma. <i>Cancer Research Communications</i> , 2024, 4, 2215-2227.	2.9	2
3	Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?. <i>Frontiers in Oncology</i> , 2022, 12, .	2.7	16
4	Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. <i>Nature Communications</i> , 2022, 13, .	13.9	137
5	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , 2021, 11, 2904-2923.	25.6	49
6	Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, .	3.6	66
7	The aryl hydrocarbon receptor regulates nucleolar activity and protein synthesis in MYC-expressing cells. <i>Genes and Development</i> , 2018, 32, 1303-1308.	4.8	42
8	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant <i>KRAS</i> Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5851-5863.	6.8	83
9	PIAS1 Promotes Lymphomagenesis through MYC Upregulation. <i>Cell Reports</i> , 2016, 15, 2266-2278.	6.4	46
10	PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. <i>Neoplasia</i> , 2016, 18, 282-293.	7.2	30
11	Corrigendum to "PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer" [Neoplasia 18 (2016) 282-293]. <i>Neoplasia</i> , 2016, 18, 457.	7.2	2
12	Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. <i>Cell Reports</i> , 2016, 16, 1614-1628.	6.4	281
13	Pias1 is essential for erythroid and vascular development in the mouse embryo. <i>Developmental Biology</i> , 2016, 415, 98-110.	1.9	17
14	Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells. <i>Cancer & Metabolism</i> , 2015, 3, .	4.9	67
15	Diet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis. <i>Cell Metabolism</i> , 2015, 21, 117-125.	27.4	39
16	Nullifying the <i>CDKN2A</i> Locus Promotes Mutant K-ras Lung Tumorigenesis. <i>Molecular Cancer Research</i> , 2014, 12, 912-923.	3.5	43
17	PML Degradation: Multiple Ways to Eliminate PML. <i>Frontiers in Oncology</i> , 2013, 3, .	2.7	21
18	RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas. <i>Cancer Discovery</i> , 2013, 3, 444-457.	25.6	109

#	ARTICLE	IF	PR CITATIONS
19	The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA. <i>Cancer Research</i> , 2012, 72, 2275-2284.	0.6	115
20	Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence. <i>EMBO Molecular Medicine</i> , 2012, 4, 594-602.	7.3	29
21	Treatment with 5-Azacytidine Accelerates Acute Promyelocytic Leukemia Leukemogenesis in a Transgenic Mouse Model. <i>Genes and Cancer</i> , 2011, 2, 160-165.	3.8	2
22	Successful Treatment of Relapsed and Refractory Extramedullary Acute Promyelocytic Leukemia With Tamibarotene. <i>Journal of Clinical Oncology</i> , 2011, 29, e534-e536.	21.6	16
23	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring <i>K-RAS</i> Mutations. <i>Cancer Research</i> , 2009, 69, 7644-7652.	0.6	141
24	A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor. <i>Cell</i> , 2006, 126, 269-283.	34.4	278
25	The Mechanisms of PML-Nuclear Body Formation. <i>Molecular Cell</i> , 2006, 24, 331-339.	13.7	493
26	In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR α blockade in the pathogenesis of acute promyelocytic leukemia. <i>Journal of Experimental Medicine</i> , 2006, 203, 821-828.	8.0	43
27	Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins. <i>Journal of the National Cancer Institute</i> , 2004, 96, 269-279.	4.8	315
28	Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. <i>Hepatology</i> , 1998, 27, 628-633.	10.3	370
29	Biologic Properties of Hepatitis B Viral Genomes with Mutations in the Precore Promoter and Precore Open Reading Frame. <i>Virology</i> , 1997, 233, 374-381.	2.3	157
30	Recent advances in the molecular biology of hepatitis B virus. <i>Bailliere's Clinical Gastroenterology</i> , 1996, 10, 207-225.	1.4	39
31	Characterization of Hepatitis B Virus Core Mutants That Inhibit Viral Replication. <i>Virology</i> , 1994, 205, 112-120.	2.3	58
32	Conserved core protein sequences in hepatitis B virus infected patients without anti-HBc. <i>Journal of Hepatology</i> , 1991, 13, 187-191.	3.6	26
33	Hepatitis B virus infection of peripheral blood mononuclear cells is common in acute and chronic hepatitis. <i>Journal of Medical Virology</i> , 1990, 31, 135-140.	3.8	34
34	Detection of hepatitis B virus transcripts in patients with chronic liver disease. <i>Journal of Hepatology</i> , 1990, 10, 180-185.	3.6	2